Literature DB >> 22099610

Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.

Alberto Briganti1, Firas Abdollah, Alessandro Nini, Nazareno Suardi, Andrea Gallina, Umberto Capitanio, Marco Bianchi, Manuela Tutolo, Niccolò Maria Passoni, Andrea Salonia, Renzo Colombo, Massimo Freschi, Patrizio Rigatti, Francesco Montorsi.   

Abstract

BACKGROUND: Computed tomography (CT) is a commonly used noninvasive procedure for prostate cancer (PCa) staging. All previous studies addressing the ability of CT scan to predict lymph node invasion (LNI) were based on historical patients treated with limited pelvic lymph node dissection (PLND).
OBJECTIVE: Assess the value of CT in predicting LNI in contemporary PCa patients treated with extended PLND (ePLND). DESIGN, SETTING, AND PARTICIPANTS: We evaluated 1541 patients undergoing radical prostatectomy and ePLND between 2003 and 2010 at a single center. All patients were preoperatively staged using abdominopelvic CT scan. All lymph nodes with a short axis diameter ≥ 10 mm were considered suspicious for metastatic involvement. INTERVENTION: All patients underwent preoperative CT scan, radical retropubic prostatectomy, and ePLND, regardless of PCa features at diagnosis. MEASUREMENTS: The performance characteristics of CT scan were tested in the overall patient population, as well as according to the National Comprehensive Cancer Network (NCCN) classification and according to the risk of LNI derived from a nomogram developed on an ePLND series. Logistic regression models tested the relationship between CT scan findings and LNI. Discrimination accuracy was quantified with the area under the curve. RESULTS AND LIMITATIONS: Overall, a CT scan that suggested LNI was found in 73 patients (4.7%). Of them, only 24 patients (32.8%) had histologically proven LNI at ePLND. Overall, sensitivity, specificity, and accuracy of CT scan were 13%, 96.0%, and 54.6%, respectively. In patients with low-, intermediate-, or high-risk PCa according to NCCN classification, sensitivity was 8.3%, 96.3%, and 52.3%, respectively; specificity was 3.6%, 97.3%, and 50.5%, respectively; and accuracy was 17.9%, 94.3%, and 56.1%, respectively. Similarly, in patients with a nomogram-derived LNI risk ≥ 50%, sensitivity, specificity, and accuracy were only 23.9%, 94.7%, and 59.3%, respectively. At multivariable analyses, inclusion of CT scan findings did not improve the accuracy of LNI prediction (81.4% compared with 81.3%; p=0.8). Lack of a central scan review represents the main limitation of our study.
CONCLUSIONS: In contemporary patients with PCa, the accuracy of CT scan as a preoperative nodal-staging procedure is poor, even in patients with high LNI risk. Therefore, the need for and the extent of PLND should not be based on the results obtained by CT scan.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22099610     DOI: 10.1016/j.eururo.2011.11.008

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  33 in total

1.  Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database.

Authors:  D Gabriele; D Collura; M Oderda; I Stura; C Fiorito; F Porpiglia; C Terrone; M Zacchero; C Guiot; P Gabriele
Journal:  World J Urol       Date:  2015-08-15       Impact factor: 4.226

2.  Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.

Authors:  Giorgio Brembilla; Paolo Dell'Oglio; Armando Stabile; Alessandro Ambrosi; Giulia Cristel; Lisa Brunetti; Anna Damascelli; Massimo Freschi; Antonio Esposito; Alberto Briganti; Francesco Montorsi; Alessandro Del Maschio; Francesco De Cobelli
Journal:  Eur Radiol       Date:  2017-12-21       Impact factor: 5.315

3.  Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Authors:  Philipp Mandel; Clemens Rosenbaum; Raisa S Pompe; Thomas Steuber; Georg Salomon; Felix K Chun; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  World J Urol       Date:  2017-08-21       Impact factor: 4.226

4.  Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT.

Authors:  Ruohua Chen; Yining Wang; Yiping Shi; Yinjie Zhu; Lian Xu; Gang Huang; Jianjun Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-02       Impact factor: 9.236

5.  Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.

Authors:  Daniela A Ferraro; Helena I Garcia Schüler; Urs J Muehlematter; Daniel Eberli; Julian Müller; Alexander Müller; Roger Gablinger; Helmut Kranzbühler; Aurelius Omlin; Philipp A Kaufmann; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-04       Impact factor: 9.236

Review 6.  Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.

Authors:  Christian Daniel Fankhauser; Cédric Poyet; Stephanie G C Kroeze; Benedikt Kranzbühler; Helena I Garcia Schüler; Matthias Guckenberger; Philipp A Kaufmann; Thomas Hermanns; Irene A Burger
Journal:  World J Urol       Date:  2018-07-20       Impact factor: 4.226

7.  Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.

Authors:  Matthias M Heck; Michael Souvatzoglou; Margitta Retz; Roman Nawroth; Hubert Kübler; Tobias Maurer; Mark Thalgott; Bettina M Gramer; Gregor Weirich; Ina-Christine Rondak; Ernst J Rummeny; Markus Schwaiger; Jürgen E Gschwend; Bernd Krause; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-03       Impact factor: 9.236

Review 8.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

9.  Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.

Authors:  Andrew D Hardie; William J Rieter; Marques L Bradshaw; Leonie L Gordon; Matthew A Young; Thomas E Keane
Journal:  World J Urol       Date:  2013-04-18       Impact factor: 4.226

Review 10.  Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.

Authors:  Jason Bailey; Morand Piert
Journal:  Curr Urol Rep       Date:  2017-09-09       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.